Rare Disease Models
There are several known rare diseases and more unknown diseases are being identified in specific patient populations. Unfortunately, there is a lack of treatment and even understanding of the mechanisms of most rare diseases. In order to meet the increasing needs of clinical treatment, it is essential to increase the research on rare diseases and the development of successful drugs. These studies rely heavily on animal models of disease in vivo.
Animal model of rare disease is an important part of the study of rare diseases because it has a complete physiological state that allows therapy to be evaluated in a more meaningful context. Although animal models do not generally represent about diseases, they can express many disease characteristics similar to those of human patients.
Creative Bioarray has developed stable and efficient preclinical disease models that can be helpful in the clinical study of rare diseases.
Our rare disease models cover the following diseases
- Huntington's disease
- Amyotrophic lateral sclerosis (ALS)
- Batten disease
- Multiple sclerosis (MS)
- Systemic lupus erythematosus (SLE)
- Muscular dystrophy
In addition, we can also use appropriate endpoints to study disease mechanisms, such as imaging, gait and movement, and cognitive testing.
Data & Figures
Figure 1. Neurotoxin models of Huntington's disease
Our team provides drug discovery services from target identification to IND enabled safety and toxicology service. We have extensive experience in developing disease models based on scientific publications.
Quotation and ordering
To discuss any of these models further or to discuss the possibility of developing alternative models, please do not hesitate to contact us.
- Rangel-Barajas. Overview of Huntington’s Disease Models: Neuropathological, Molecular, and Behavioral Differences. Curr. Protoc. Neurosci. 83, e47 (2018).
For research use only. Not for any other purpose.